President Donald Trump’s nominees for NIH director and FDA commissioner sailed through their respective confirmation hearings this week, facing few difficult questions and offering few …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Investigational therapies may soon change the treatment landscape for chronic inflammatory demyelinating polyneuropathy (CIDP). “Despite the fact that we have some good standard-of-care therapies —
Single and multiple oral doses of GM-1020, a novel non-competitive NMDA channel blocker, were well-tolerated with no serious or severe adverse events observed and confirmed
T-cell engagers are a class of immunotherapies that direct T cells to recognise and eliminate cancer cells. Credit: skynesher via Getty Images. US-based Normunity has